(Press-News.org) Sarah Wakeman, MD, Senior Medical Director for Substance Use Disorder at Mass General Brigham, is the co-senior author and Will Oles, BS, of Harvard Medical School, is a corresponding author of a paper published in the Journal of General Internal Medicine, “Geographic Trends in Opioid and Polysubstance Overdose Deaths in the US, 2014-2023.”
Q: How would you summarize your study for a lay audience?
In May 2024, the Centers for Disease Control (CDC) announced a national decline in the rate of drug overdose deaths for the first time since 2018. However, little is known about how this decline varies by geographic region.
To address this gap, we analyzed US opioid overdose deaths by region, finding that opioid-related mortality increased in the western US despite a decrease in other regions between 2022 and 2023.
This regional divergence was driven by an increase in overdoses due to fentanyl or a combination of fentanyl and stimulants (e.g., methamphetamine).
These findings highlight the evolving nature of the overdose crisis and suggest the need for region-specific strategies to address differing patterns of substance use and overdose risk.
Q: What knowledge gap does your study help to fill?
Given recent reports of national improvements in opioid-related mortality, we sought to understand how trends in opioid overdoses––particularly those involving combinations of opioids with other substances––have shifted over time across different regions of the US.
Q: What methods or approach did you use?
We examined publicly available death certificate data from the CDC’s WONDER database to identify all opioid-related deaths reported in the US between 2014 and 2023.
Q: What did you find?
Between 2022 and 2023, we found that opioid overdose deaths decreased in non-West regions but continued to rise in the western US by 14%.
Beginning in 2019, rates of overdoses that co-involved both fentanyl and a stimulant accelerated across all US regions.
Overdoses involving fentanyl and cocaine were more common in non-West regions, while overdoses involving fentanyl and methamphetamine were more common in the West.
Nationally, around one in three fentanyl-related deaths now involve stimulants, with states in the West nearing one in two.
Q: What are the implications?
Our findings of a continued increase in opioid overdose deaths in the West, masked by a decline in mortality nationally, underscore an ongoing shift in the landscape of the opioid overdose crisis.
The emergence of these distinct overdose patterns highlight the need for ongoing surveillance of these substances in local drug markets, equitable access to medications for opioid use disorder and investment in therapies for stimulant use disorder.
Q: What are the next steps?
Ongoing surveillance of regional opioid mortality trends will be essential as new data emerges nationally. Future research should also investigate the root causes of geographic disparities to help guide targeted public health responses and inform policy development.
Authorship: In addition to Wakeman and Oles, additional authors include Michael Liu and Marc Larochelle.
Paper cited: Oles W C, et al. “Geographic Trends in Opioid and Polysubstance Overdose Deaths in the US, 2014-2023” Journal of General Internal Medicine. DOI: 10.1007/s11606-025-09589-1
Funding: N/A
Disclosures: Dr. Wakeman reported being an author for UpToDate and a textbook editor for Springer and Wolters Kluwer.
END
Research spotlight: regional disparities in opioid overdose mortality persist despite national decline
2025-06-02
ELSE PRESS RELEASES FROM THIS DATE:
Fighting myeloma with fiber: Plant-based diet offers promise
2025-06-02
Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.
Multiple myeloma is often preceded by early, non-cancerous conditions involving abnormal plasma cells, a type of white blood cell found in the bone marrow. Having a high body weight, ...
What makes someone leave a Medicare Advantage plan?
2025-06-02
More than half of older Americans now get their Medicare coverage through an insurance company’s Medicare Advantage plan. But many go on to switch plans or even leave for traditional Medicare when Open Enrollment comes around each autumn.
Researchers have had a hard time getting access to data that could help them understand what drives these changes, which have major implications for federal spending on Medicare as well as individuals’ health.
Now, a new study in the June issue of Health Affairs peels back the curtain on what motivates people to switch ...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
2025-06-02
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes.
First-in-class antibody-drug conjugate, pivekimab sunirine (PVEK), was safe and effective.
PVEK achieved an overall response rate of 85% and complete response rate of 70% as frontline treatment in newly diagnosed patients with BPDCN.
Findings suggest this treatment should be considered as a new standard of care for these patients.
ABSTRACT: 6502
CHICAGO, JUNE 2, 2025 ― The first-in-class ...
Advancing personalized medicine through pharmacogenomics: Insights from Ochsner Health
2025-06-02
In a report recently published in the American Journal of Health-System Pharmacy, the Ochsner Health system delves into the multifaceted implementation of pharmacogenomics—a rapidly evolving field that examines how genetics influence individual responses to medication. This comprehensive article, led by Dr. Catherine Oliver and a team of experts in pharmacy services, provides an insightful blueprint for health systems aiming to integrate pharmacogenomics into clinical practice.
"Pharmacogenomics embodies a new frontier in precision medicine, enabling us to fine-tune treatments ...
Researchers tested an asthma drug for treating alcoholism. It failed except with this group
2025-06-02
Key takeaways
Ibudilast is a drug approved in Japan for the treatment of asthma and post-stroke dizziness by targeting inflammation; previous research suggested it could also help people reduce their drinking.
A UCLA clinical trial, however, has now shown that ibudilast worked no better than a placebo for trial participants in reducing alcohol consumption, although it did have a positive effect on women.
Women tend to have higher levels of inflammation than men, and the results of ibudilast testing with women point toward ...
Set it and forget it: Autonomous structures can be programmed to jump days in advance
2025-06-02
Researchers have created dynamic structures that leap into the air on a predetermined schedule without intervention from computers or external stimuli. Precisely when these “metashells” jump, and how high they jump, is engineered into the physical structure of the materials.
“There are structures that ‘jump’ immediately when loading is removed – such as when a coiled spring is released,” says Jie Yin, corresponding author of a paper on the work and an associate professor of mechanical engineering at North Carolina State University. “We wanted to create a structure that does not rely on external stimuli and allows us to dictate the timing ...
Iron from coal, steel industries alters North Pacific ecosystem
2025-06-02
Along with nutrients like nitrogen and phosphorus, iron is essential for the growth of microscopic phytoplankton in the ocean. However, a new study led by oceanographers at the University of Hawai‘i (UH) at Mānoa revealed that iron released from industrial processes, such as coal combustion and steel making, is altering the ecosystem in the North Pacific Transition Zone, a region just north of Hawai‘i that is important for fisheries in the Pacific. The study was published today in the Proceedings of the National Academy of Sciences USA.
“This ...
Canadian researcher receives funding from ARIA to unlock potential of plants
2025-06-02
Imagine a world where crops can thrive regardless of climate or disease and provide all the essential nutrients our bodies need. Researchers at Western University’s Schulich School of Medicine & Dentistry are now part of a U.K.-based initiative to explore that very possibility.
The Advanced Research + Invention Agency (ARIA), the U.K.’s research and development funding agency, announced June 2 that Schulich Medicine & Dentistry professor Bogumil Karas has been named ...
Visionary support from Veale Foundation will establish university hospitals Veale Healthcare Transformation Institute
2025-06-02
CLEVELAND – A new visionary gift from the Veale Foundation will establish the University Hospitals Veale Healthcare Transformation Institute. The $23.5 million in support represents an investment in University Hospitals’ value-based care initiatives. Peter J. Pronovost, MD, PhD, UH Chief Quality and Clinical Transformation Officer, will serve as the institute’s founding and first president.
“Healthcare today tells a story of scarcity – it harms too often, costs too much and learns and ...
Investigating cocaine addiction using fruit flies
2025-06-02
In a new JNeurosci paper, Adrian Rothenfluh and colleagues from the University of Utah developed a fruit fly model of cocaine self-administration that can be used to explore the genetic underpinnings of cocaine addiction.
To model voluntary cocaine intake in fruit flies, or Drosophila melanogaster, the researchers first assessed cocaine consumption and preferences of this insect. Cocaine was innately aversive to fruit flies because it activated their bitter-sensing receptors. In other words, the fruit flies did not like cocaine’s ...